This company listing is no longer active
Resumen de acción 2K7
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 2 riesgos adicionales
Competidores de TCR2 Therapeutics Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.44 |
| 52 Week High | US$4.00 |
| 52 Week Low | US$0.75 |
| Beta | 1.93 |
| 1 Month Change | -11.64% |
| 3 Month Change | 30.44% |
| 1 Year Change | -32.74% |
| 3 Year Change | -85.13% |
| 5 Year Change | n/a |
| Change since IPO | -88.56% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 2K7 | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | -10.3% | 2.1% | -1.0% |
| 1Y | -32.7% | -22.4% | 2.0% |
Rentabilidad vs. Industria: 2K7 underperformed the German Biotechs industry which returned -7.6% over the past year.
Rentabilidad vs. Mercado: 2K7 underperformed the German Market which returned -7% over the past year.
Volatilidad de los precios
| 2K7 volatility | |
|---|---|
| 2K7 Average Weekly Movement | 14.5% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: 2K7's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: 2K7's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2015 | 58 | Garry Menzel | www.tcr2.com |
Resumen de fundamentos de TCR2 Therapeutics Inc.
| Estadísticas fundamentales de 2K7 | |
|---|---|
| Capitalización bursátil | €54.27m |
| Beneficios(TTM) | -€152.33m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-0.4x
Ratio precio-beneficio (PE)¿Está 2K7 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 2K7 | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$163.10m |
| Beneficios | -US$163.10m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -4.15 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado 2K7 a largo plazo?
Ver rendimiento histórico y comparativa